stockportfolio.pro
Aquestive Therapeutics, Inc. (AQST)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Aquestive Therapeutics, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.92M | $67.43M | $52.61M | $45.85M | $50.83M | $47.68M | $50.58M | $57.56M | $44.55M |
| Gross profit | — | — | $32.25M | $32.88M | — | $28.29M | $29.75M | $39.69M | $25.99M |
| Net income | $-8.94M | $-61.38M | $-66.25M | $-55.78M | $-70.54M | $-54.41M | $-7.87M | $-44.14M | $-83.78M |
| Net margin | -13.4% | -91.0% | -125.9% | -121.7% | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
Source: Aquestive Therapeutics, Inc. SEC filings (10-K).
Explore 9 years of Aquestive Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AQST in your portfolio →
Aquestive Therapeutics, Inc. financial history by metric
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics, Inc. — frequently asked questions
What is Aquestive Therapeutics, Inc.'s revenue?
Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.55M for fiscal year 2025, down 22.6% from the prior year, according to its SEC filings.
Is Aquestive Therapeutics, Inc. profitable?
No — AQST reported a net loss of $-83.78M in fiscal 2025.
What is AQST's P/E ratio?
Aquestive Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Aquestive Therapeutics, Inc. growing?
AQST's revenue grew at roughly -0.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Aquestive Therapeutics, Inc. have?
As of fiscal year 2025, AQST carried roughly $37.51M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Aquestive Therapeutics, Inc.'s gross margin?
AQST's gross margin was 58.3% in fiscal 2025 — gross profit of $25.99M on revenue of $44.55M.
What is Aquestive Therapeutics, Inc.'s market cap?
Aquestive Therapeutics, Inc. (AQST) has a market capitalization of about $516.85M, based on the latest data in our nightly-refreshed cache.
When does Aquestive Therapeutics, Inc.'s fiscal year end?
AQST's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Aquestive Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.